Boletín de THE ONCOLOGIST N°35 ACEPTA ARTÍCULO DEL ... … · Jiménez, Fernando Herazo, Jorge...
1
Linfadenectomia para-órtica en pacientes con cáncer de cuello uterino con histerectomía abandonada. Investigadores: Gabriel Jaime Rendón, René Pareja Subtipos moleculares de cáncer de seno en mujeres latinoamericanas premenopausicas en una población multicéntrica basada en un estudio de casos y controles (PRECAMA). Prueba piloto. Investigadores: Mauricio Borrero, Gloria Sánchez, Marta Valencia, Armando Baena, Astrid Bedoya, Catalina Villa, María Maldonado, Carolina López, Isabel Garcés, Carolina Echeverri, Rodolfo Gómez, Alejo Jiménez, Fernando Herazo, Jorge Madrid, Gonzalo Angel, Pedro Reyes, María E Montoya, Andrés Ossa. Percepción de los padres de familia sobre el acceso a los servicios oncológicos de niños menores de 12 años atendidos en el Instituto de Cancerología de Medellín, entre enero - junio de 2014. Investigadores: María Alejandra García Zapata, Carolina Palacio González, Yudi Alejandra Murillo Gómez, Jalcy Yuleicy Ocampo Galeano Abstract PROYECTOS FINALIZADOS Investigación Boletín de N°35 THE ONCOLOGIST ACEPTA ARTÍCULO DEL INSTITUTO DE CANCEROLOGÍA Marzo 2016 Headings: Numerous epidemiological factors affect the probability of developing breast and/or ovarian cancer, but no predictor is as determinant as inheriting a mutation in BRCA1 or BRCA2. The “founder effect” concept explains the reduced genetic variability in some populations through the theory that new populations can be formed from a reduced number of individuals, so the new population would carry only a small fraction of the genetic variability of the original population. Purpose: The main purpose of this review is to provide an update on the state of the art in founder mutations and some recurrent mutations that have been recently described in Latin America. Methods: A literature search was performed in the electronic databases of PUBMED, EMBASE, LILACS and BIREME using the terms BRCA1, BRCA2, Founder Mutation, Latin American Population and Hispanic. A total of 62 papers were identified, of which 38 were selected because they were considered relevant for this review. Each result is shown per country. Results: In Latin America, clear founder effects have been reported in Mexico (BRCA1 del exons 9-12), Brazil (BRCA1 5382insC, BRCA2 c.156_157insAlu), Colombia (BRCA1 3450del4, A1708E and BRCA2 3034del4) and in Unidad de Investigación Grupo de Investigación en Cáncer IDC Correo: [email protected] Teléfono: 340 93 93 ext. 5426 - 5461 Medellín - Colombia Resultados clínicos y sus factores asociados en pacientes con osteosarcoma y sarcoma de Ewing tratados en el Instituto de Cancerología Las Américas, Medellín (IDC) entre 1998 y 2010. Investigadores: Gustavo Adolfo Molina Uribe, Hernán Darío Gallego Eusse, Lorena Bejarano Pineda, Miguel Andrés Murcia Hernández, Gloria Elena Suárez Vallejo, Ana María Sánchez Henao, Gabriel Jaime Cano Restrepo. The Oncologist aceptó para publicación el artículo “Founder and Recurrent Mutations in the BRCA1 and BRCA2 genes in Latin American Countries – State of the Art and Literature Review” realizado por Carlos Andrés Ossa y Diana Torres. El factor de impacto de la revista en 2015 fue 4.865 INICIAN PROYECTOS EN CÁNCER GÁSTRICO CON LA INDUSTRIA FARMACÉUTICA Latinas residing in Southern California (BRCA1 185delAG, IVS5+1G>A, S955X and R1443X) [53]. Of these, mutation BRCA1 3450del4 has also been reported in Brazil and Chile, while mutation BRCA2 3034del4 has been reported in Argentina and Peru. These data support the idea that although most Hispanic populations are the result of a mixture between Europeans, Africans and Amerindians, the relative proportion of each genetic component varies throughout the Hispanic populations, making it necessary to identify the mutations characteristic of each population to generate mutation profiles adjusted to each one of them. Conclusions: In Latin American countries and even among regions of the same country, there is great heterogeneity from the ancestral point of view. Therefore, the “Latinas” should not be analyzed like other population groups without taking into account their genetic ancestry. The presence of founder mutations in specific population groups represents a cost-effective analysis. The importance of determining the founder mutations lies mainly in the decrease in costs. If we manage to decrease costs, screenings could be offered more widely and could cover a larger number of women. Estudio clínico de Fase III randomizado, con selección según el estado del biomarcador, controlado con tratamiento activo, parcialmente ciego, de Pembrolizumab como monoterapia y en combinación con Cisplatino+5-Fluorouracilo en comparación con Placebo+Cisplatino+5- Fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica avanzado (3475-062) Estudio clínico fase III, abierto, randomizado, de pembrolizumab comparado con paclitaxel en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado que empeoraron después del tratamiento de primera línea con platino y fluoropirimida (3475-061)
Transcript of Boletín de THE ONCOLOGIST N°35 ACEPTA ARTÍCULO DEL ... … · Jiménez, Fernando Herazo, Jorge...
Linfadenectomia para-órtica en pacientes con cáncer de cuello uterino con histerectomía abandonada.Investigadores: Gabriel Jaime Rendón, René Pareja
Subtipos moleculares de cáncer de seno en mujeres latinoamericanas premenopausicas en una población multicéntrica basada en un estudio de casos y controles (PRECAMA). Prueba piloto.
Investigadores: Mauricio Borrero, Gloria Sánchez, Marta Valencia, Armando Baena, Astrid Bedoya, Catalina Villa, María Maldonado, Carolina López, Isabel Garcés, Carolina Echeverri, Rodolfo Gómez, Alejo
Jiménez, Fernando Herazo, Jorge Madrid, Gonzalo Angel, Pedro Reyes, María E Montoya, Andrés Ossa.
Percepción de los padres de familia sobre el acceso a los servicios oncológicos de niños menores de 12 años atendidos en el Instituto de Cancerología de Medellín, entre enero - junio de 2014.
Investigadores: María Alejandra García Zapata, Carolina Palacio González, Yudi Alejandra Murillo Gómez, Jalcy Yuleicy Ocampo Galeano
Abstract
PROYECTOS FINALIZADOS
InvestigaciónBoletín de
N°35THE ONCOLOGIST
ACEPTA ARTÍCULO DEL INSTITUTO DE CANCEROLOGÍA
Marzo 2016
Headings: Numerous epidemiological factors affect the probability of developing breast and/or ovarian cancer, but no predictor is as determinant as inheriting a mutation in BRCA1 or BRCA2. The “founder effect” concept explains the reduced genetic variability in some populations through the theory that new populations can be formed from a reduced number of individuals, so the new population would carry only a small fraction of the genetic variability of the original population. Purpose: The main purpose of this review is to provide an update on the state of the art in founder mutations and some recurrent mutations that have been recently described in Latin America. Methods: A literature search was performed in the electronic databases of PUBMED, EMBASE, LILACS and BIREME using the terms BRCA1, BRCA2, Founder Mutation, Latin American Population and Hispanic. A total of 62 papers were identified, of which 38 were selected because they were considered relevant for this review. Each result is shown per country. Results: In Latin America, clear founder effects have been reported in Mexico (BRCA1 del exons 9-12), Brazil (BRCA1 5382insC, BRCA2 c.156_157insAlu), Colombia (BRCA1 3450del4, A1708E and BRCA2 3034del4) and in
Unidad de InvestigaciónGrupo de Investigación en Cáncer IDCCorreo: [email protected]éfono: 340 93 93 ext. 5426 - 5461
Medellín - Colombia
Resultados clínicos y sus factores asociados en pacientes con osteosarcoma y sarcoma de Ewing tratados en el Instituto de Cancerología Las Américas, Medellín (IDC) entre 1998 y 2010.Investigadores: Gustavo Adolfo Molina Uribe, Hernán Darío Gallego Eusse, Lorena Bejarano Pineda, Miguel Andrés Murcia Hernández, Gloria Elena Suárez Vallejo, Ana María Sánchez Henao, Gabriel Jaime Cano Restrepo.
The Oncologist aceptó para publicación el artículo “Founder and Recurrent Mutations in the BRCA1 and BRCA2 genes in Latin American Countries – State of the Art and Literature Review” realizado por Carlos Andrés Ossa y Diana Torres. El factor de impacto de la revista en 2015 fue 4.865
INICIAN PROYECTOS EN CÁNCER GÁSTRICO CON LA INDUSTRIA FARMACÉUTICA
Latinas residing in Southern California (BRCA1 185delAG, IVS5+1G>A, S955X and R1443X) [53]. Of these, mutation BRCA1 3450del4 has also been reported in Brazil and Chile, while mutation BRCA2 3034del4 has been reported in Argentina and Peru. These data support the idea that although most Hispanic populations are the result of a mixture between Europeans, Africans and Amerindians, the relative proportion of each genetic component varies throughout the Hispanic populations, making it necessary to identify the mutations characteristic of each population to generate mutation profiles adjusted to each one of them. Conclusions: In Latin American countries and even among regions of the same country, there is great heterogeneity from the ancestral point of view. Therefore, the “Latinas” should not be analyzed like other population groups without taking into account their genetic ancestry. The presence of founder mutations in specific population groups represents a cost-effective analysis. The importance of determining the founder mutations lies mainly in the decrease in costs. If we manage to decrease costs, screenings could be offered more widely and could cover a larger number of women.
Estudio clínico de Fase III randomizado, con selección según el estado del biomarcador, controlado con tratamiento activo, parcialmente ciego, de Pembrolizumab como monoterapia y en combinación con Cisplatino+5-Fluorouracilo en comparación con Placebo+Cisplatino+5- Fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica avanzado (3475-062)
Estudio clínico fase III, abierto, randomizado, de pembrolizumab comparado con paclitaxel en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado que empeoraron después del tratamiento de primera línea con platino y fluoropirimida (3475-061)
